The effect of CD34+ cell-containing autologous platelet-rich plasma injection on pattern hair loss: a preliminary study

1Kangskin Clinic and 2Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
*Correspondence: S.B. Cho. E-mail: sbcho@yuhs.ac

Abstract
Background Mobilized CD34+ cells in peripheral blood have angiogenic potential, which is an important factor in active hair growth. In addition, activated autologous platelet-rich plasma (PRP) has been reported to induce the proliferation of dermal papilla cells.
Objectives To investigate the clinical efficacy of interfollicular injection of CD34+ cell-containing PRP preparation for pattern hair loss.
Patients and methods CD34+ cell-containing PRP preparation was injected on the scalps of 13 patients with pattern hair loss, and 13 patients were treated with interfollicular placental extract injection as a control. The numbers of platelets in PRP were microscopically counted and CD34+ cells were evaluated with flow cytometry.
Results Three months after the first treatment, the patients presented clinical improvement in the mean number of hairs, 20.5 ± 17.0% (P < 0.0001), mean hair thickness, 31.3 ± 30.1% (P < 0.0001), and mean two-point score, 84.4 ± 51.7% (P < 0.0001) compared with baseline values. At 6 months, the patients presented clinical improvement in mean hair count, 29.2 ± 17.8% (P < 0.0001), mean hair thickness, 46.4 ± 37.5% (P < 0.0001), and mean two-point score, 121.3 ± 66.8% (P < 0.0001) compared with baseline. The MIXED procedure revealed that CD34+ cell-containing PRP treatment presented a higher degree of improvement than placental extract treatment in hair thickness (P = 0.027) and overall clinical improvement (P = 0.023).
Conclusion Our data suggest that the interfollicular injection of autologous CD34+ cell-containing PRP preparation has a positive therapeutic effect on male and female pattern hair loss without remarkable major side-effects.

Introduction
Platelet-rich plasma (PRP) has been used to promote wound healing processes in hard and soft tissues in various medical conditions.1–3 Prepared plasma contains highly concentrated platelets and releases numerous proteins composed of growth factors, chemokines and cytokines in platelet α-granules, which stimulate cell proliferation and differentiation.2–4 In addition, the role of PRP for the treatment of pattern hair loss has been demonstrated in recent reports.1,2,4 Uebel et al.6 demonstrated that follicular unit implantation with patients’ autologous PRP resulted in a higher yield of follicular units. Activated autologous PRP has been reported to induce the proliferation of dermal papilla cells by up-regulating fibroblast growth factor 7 (FGF-7) and β-catenin as well as extracellular signal-related kinase (ERK) and Akt signalling.7
Anagen-associated angiogenesis has been suggested as one of the important factors in active hair growth.7 In addition, the angiogenic factor of vascular endothelial growth factor (VEGF) also originated from the keratinocytes in the outer root sheath and fibroblasts in dermal papilla.7–9 Therefore, the currently available treatment modalities for pattern hair loss have been shown to modulate angiogenesis and enhance blood flow.10 Injection of PRP has been demonstrated to improve cutaneous ischaemic conditions and to increase vascular structures around hair follicles.1,11
Bone marrow-derived CD34+ haematopoietic stem cells have shown beneficial effects in inflammatory and non-inflammatory diseases by promoting angiogenesis and/or vasculogenesis, especially in conditions of myocardial ischaemia. However, it has been suggested that the mobilized CD34+ cells in peripheral blood naturally decrease in the number of circulating cells and lose angiogenic potential with age. As α-granules in PRP include platelet-derived angiogenesis factor, platelet-derived endothelial growth factor and VEGF, we hypothesized that the clinical application of CD34+ cells in autologous PRP preparation can be effectively used for the treatment of male and female pattern hair loss.

**Patients and methods**

**Patients**
A total of 15 male patients (mean age: 36.1; age range: 26–62) with male pattern hair loss and 11 female patients (mean age: 38.7; age range: 22–55) with female pattern hair loss were reviewed in this study. The patient characteristics are summarized in Table 1. Patients, who had undergone concomitant treatments, including topical medications (such as minoxidil, alphatradiol, prostaglandin analogues, retinoids, melatonin and corticosteroid), oral medications (such as finasteride, dutasteride and antiandrogens), mesoanalogues, retinoids, melatonin and corticosteroid), oral medications (such as finasteride, dutasteride and antiandrogens), mesotherapy, non-ablative fractional laser treatment, low-level laser therapy, interfollicular PRP injection and hair transplantation, were also excluded. In addition, the numbers of platelets in PRP obtained from all participants were microscopically counted. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

**Treatment protocol**
CD34+ cell-containing PRP was prepared using SmartPreP®2 APC+TM (Harvest Technologies Corp., Plymouth, MA, USA) in participants (n = 13; seven males and six females; mean age: 37.6; age range: 22–62) who provided informed consent. Briefly, 60 mL of blood obtained from the participants was transferred to tubes containing 8 mL of 4% sodium citrate solution (Baxter Healthcare Corp., Deerfield, IL, USA). Then, the blood was centrifuged with the SmartPreP®2 platelet concentrate system (Harvest Technologies Corp.). The scalp was cleansed with 70% alcohol, and local anaesthesia of 2% lidocaine with 1:100 000 epinephrine (3–5 mL) was injected on the frontal and parietal areas. Then, CD34+ cell-containing PRP preparation (4 mL) was injected on the scalp at the amount of 0.05–0.1 mL/cm². Interfollicular injection of CD34+ cell-containing PRP preparation was performed twice with a 3-month interval.

The second group of patients (n = 13; eight males and five females; mean age: 36.8; age range: 26–47) was treated with interfollicular placental extract injection. Placental extracts are enriched in bioactive molecules, including growth factors, amino acids, nucleic acids, vitamins, fatty acids and minerals, and have been used for various purposes. The scalp was cleansed with 70% alcohol, and 2 mL of placental extract (Melsmon®; Melsmon Pharmaceutical Co., Ltd., Tokyo, Japan) was injected on the frontal and parietal areas without local anaesthesia. During the treatment, a cooling device with cold air (−10 °C; Zimmer MedizinSystems, Irvine, CA, USA) was briefly used to relieve pain. The placental extract was delivered to the patients at 1-week intervals for 6 months. Concomitant treatment of 1 mg of oral finasteride was initiated in male patients, which are summarized in Table 1. All of the participants in both groups were advised to avoid the use of topical medications (such as minoxidil,

**Table 1** Baseline patient demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Platelet-rich plasma (PRP) preparation treatment</th>
<th>Platelet concentration of PRP preparation (platelets/μL)</th>
<th>Placental extract treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt.</td>
<td>Sex/age</td>
<td>Concomitant treatment</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>----------------------</td>
</tr>
<tr>
<td>1</td>
<td>M/52</td>
<td>Finasteride</td>
</tr>
<tr>
<td>2</td>
<td>M/30</td>
<td>Finasteride</td>
</tr>
<tr>
<td>3</td>
<td>M/25</td>
<td>Finasteride</td>
</tr>
<tr>
<td>4</td>
<td>F/22</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>M/34</td>
<td>Finasteride</td>
</tr>
<tr>
<td>6</td>
<td>M/42</td>
<td>Finasteride</td>
</tr>
<tr>
<td>7</td>
<td>M/62</td>
<td>Finasteride</td>
</tr>
<tr>
<td>8</td>
<td>M/26</td>
<td>Finasteride</td>
</tr>
<tr>
<td>9</td>
<td>F/33</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>F/48</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>F/54</td>
<td>–</td>
</tr>
<tr>
<td>12</td>
<td>F/31</td>
<td>–</td>
</tr>
<tr>
<td>13</td>
<td>F/30</td>
<td>–</td>
</tr>
</tbody>
</table>
alphatradiol, prostaglandin analogues, retinoids, melatonin and corticosteroid), non-ablative fractional laser treatment, low-level laser therapy and hair transplantation.

**Objective and subjective evaluations**

Hair measurement was performed using a computerized handheld USB camera PT system (Follioscope®, LeedM Corporation, Seoul, Korea) at baseline and 3 and 6 months after the first treatment. Digital images of the hairs were obtained at 40-fold magnification at reference points by a phototrichogram scalp measurement method using a headband and a tapeline, and both the number and the thickness of hairs were measured with Follioscope PT® software (LeedM Corporation). The reference points included the ‘P’ (standard point), ‘V’ (Kang’s point), and ‘Fr’ and ‘Fl’ points, as described in previous report. To calculate the baseline degree of disease progression and overall clinical improvement, a two-point scoring method with ‘P’ point (intersection of the posterior mid-sagittal line and the horizontal line connecting both upper ear roots; Fig. 1a, b) as a standard point and ‘V’ point (intersection of the mid-sagittal line and the coronal line connecting both tips of the tragus; Fig. 1c, d) as a diseased point were used following the formula below.

\[
\frac{\text{No (P)} - \text{No (V)}}{\text{No (P)}} \times 50 + \frac{\text{Th (P)} - \text{Th (V)}}{\text{Th (P)}} \times 50
\]

= baseline degree of disease progression(%).

Where No (P) is the number of hairs measured at the ‘P’ point; No (V) is the number of hairs measured at the ‘V’ point; Th (P) is the mean thickness of hairs measured at the ‘P’ point; and Th (V) is the mean thickness of hairs measured at the ‘V’ point.

Six months after the first treatment, patients were asked to report the incidence and duration of side-effects of the treatment, including scalp oedema, blistering, bleeding, oozing, scaling or crusting, erythema or increased hair loss.

**Flow cytometry**

PRP preparation and the equal amount of whole blood were obtained from two healthy volunteers, who had provided informed consent, for cytometric analysis of CD34+ cells in peripheral blood. The surface staining of cellular components in PRP preparations was performed by staining with Cy7-conjugated anti-CD34 polyclonal antibody (Bioss, Woburn, MA, USA) at the concentration of 2 μg/mL. Fluorescence was detected with an LSRII (BD Bioscience, San Jose, CA, USA), and then standard

---

**Figure 1** Photos demonstrating (a and b) ‘V’ point (intersection of the mid-sagittal line and the coronal line connecting both tips of the tragus) and (c and d) ‘P’ point (intersection of the posterior mid-sagittal line and the horizontal line connecting both upper ear roots).
acquisition and analysis of the data were obtained through FACS-Diva software version 6.1.3 (BD Bioscience).

**Statistical analysis**
The normality test was performed using Kolmogorov–Smirnov test, and significance differences were assessed by parametric criteria. Results were analysed by the MIXED procedure with Bonferroni post-hoc test, t-test and Chi-squared test using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). Differences were considered statistically significant when the $P$-value was less than 0.05.

**Results**
Flow cytometry was performed using PRP preparation and an equal amount of peripheral blood in two healthy volunteers. One participant presented 6.7 cells/μL of CD34+ cells in peripheral blood, whereas those in the autologous PRP preparation were 31.1 cells/μL (Fig. 2a, b). The other participant presented 6.6 cells/μL of CD34+ cells in peripheral blood, whereas those in the autologous PRP preparation were 13.9 cells/μL (Fig. 2c, d).

At baseline, there were no statistical differences in hair count ($P > 0.05$), hair thickness ($P > 0.05$), or the degree of disease progression ($P > 0.05$) between the PRP treatment group and placental extract treatment group. The participants presented a mean degree of disease progression of 24.0 ± 11.0 in the PRP treatment group and 23.5 ± 10.1 in the placental extract treatment group, calculated by a two-point scoring method. Platelet counts in autologous PRP preparations, which were evaluated for each patient with PRP treatment, revealed a mean of 1,484,538.5 ± 335,123.5 platelets/μL (Table 1), whereas their peripheral blood had a mean of 241,750.0 ± 37,051.1 platelets/μL. Therefore, we obtained a mean 5.9-fold increase in concentrated platelets in autologous PRP preparation compared to the peripheral blood.

At 3 months after the first treatment, the patients treated with CD34+ cell-containing PRP presented clinical improvement of the mean number of hairs, $20.5 \pm 17.0\% \ (P < 0.0001)$; mean hair thickness, $31.3 \pm 30.1\% \ (P < 0.0001)$; and mean two-point scores, $84.4 \pm 51.7\% \ (P < 0.0001)$ compared with baseline values (Fig. 3). In patients treated with placental extracts, mean hair count ($14.7 \pm 11.9\%, \ P = 0.0015$), hair thickness ($14.5 \pm 13.8\%, \ P = 0.037$), and two-point score mean ($43.8 \pm 15.3\%, \ P < 0.0001$) were improved. The MIXED procedure revealed that CD34+ cell-containing PRP treatment presented a higher degree of improvement than placental extract treatment in two-point scores ($P = 0.018$), but not in hair thickness ($P > 0.05$) or hair count ($P > 0.05$) (Table 2).

At 6 months after the first treatment, the patients treated with CD34+ cell-containing PRP presented clinical improvement of mean hair count ($29.2 \pm 17.8\%, \ P < 0.0001$), mean hair thickness ($46.4 \pm 37.5\%, \ P < 0.0001$), and mean two-point score ($121.3 \pm 66.8\%, \ P < 0.0001$) compared with baseline (Fig. 4–6). In patients treated with placental extracts, mean hair count ($26.0 \pm 14.6\%, \ P < 0.0001$), hair thickness ($21.4 \pm 14.6\%$,
and two-point score (72.8 ± 15.0%, \( P < 0.0001 \)) were improved compared with baseline. The MIXED procedure revealed that CD34+ cell-containing PRP treatment presented a higher degree of improvement than placental extract treatment in hair thickness (\( P = 0.027 \)) and two-point score (\( P = 0.023 \)), but not in hair count (\( P > 0.05 \)) (Table 2).

Age, sex and concomitant treatment did not significantly affect hair count (\( P > 0.05 \)), hair thickness (\( P > 0.05 \)) or the degree of disease progression (\( P > 0.05 \)) in either the PRP-treated group or the placental extract-treated group at 3 months or 6 months. In this study, side-effects of treatment included pain during the treatment with PRP treatment and placental extract treatment, transient post-treatment erythema and edema in the PRP treatment group (\( n = 3; 23.1\% \)) and folliculitis in the placental extract treatment group (\( n = 1; 7.7\% \)). Other possible side-effects, such as secondary bacterial or viral infection, post-therapy blister formation, hypopigmentation, worsening of hair loss or scarring, were not observed.

**Discussion**

Current strategies for the treatment of pattern hair loss are mainly focussed on promoting cellular proliferation and differentiation during the hair growth cycle. Topical minoxidil promotes hair growth by stimulating epithelial cell mitosis and VEGF production as well as prolonging the anagen phase. Increased Bcl-2/Bax ratio and activated ERK and Akt by minoxidil reportedly promote...
the survival of dermal papilla cells. Oral finasteride also induces the prolongation of anagen hairs, which results in gradual thickening and elongation of the hairs. In addition, finasteride has been shown to reduce the pattern hair loss-associated increased expression of caspases and apoptosis inhibitors and therefore is ultimately suggested to activate anagen hair growth.

Anti-apoptotic effects of activated PRP have been suggested as one of the major contributing factors stimulating hair growth. PRP-induced activation of anti-apoptotic regulators, such as the Bcl-2 protein and Akt signalling, prolongs the survival of dermal papilla cells during the hair cycle. In addition, the up-regulation of FGF-7/β-catenin signalling pathways with PRP treatment is suggested to stimulate hair growth by inducing follicular stem cell differentiation as well as prolonging the anagen phase of the hair growth cycle.

In this study, SmartPreP®/2 APC+™ (Harvest Technologies Corp.) and SmartPreP®/2 platelet concentrate systems (Harvest Technologies Corp.), approved by the US Food and Drug Administration, were used to prepare CD34+ cell-containing platelet-rich plasma preparation.

Table 2 Clinical efficacies of platelet-rich plasma preparation (PRP) treatment and placental extract (PE) treatment

<table>
<thead>
<tr>
<th></th>
<th>PRP treatment*</th>
<th>PE treatment*</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group</td>
<td>Time</td>
<td>Group x time</td>
</tr>
<tr>
<td>Hair count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>43.2 ± 2.5</td>
<td>43.0 ± 2.5</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>3 months</td>
<td>51.2 ± 2.4</td>
<td>49.0 ± 2.4</td>
<td>P &lt; 0.0001</td>
</tr>
<tr>
<td>6 months</td>
<td>55.5 ± 2.1</td>
<td>52.7 ± 2.1</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>Hair thickness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.030 ± 0.002</td>
<td>0.034 ± 0.002</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>3 months</td>
<td>0.039 ± 0.002</td>
<td>0.039 ± 0.002</td>
<td>P &lt; 0.0001</td>
</tr>
<tr>
<td>6 months</td>
<td>0.043 ± 0.002</td>
<td>0.041 ± 0.002</td>
<td>P = 0.03</td>
</tr>
<tr>
<td>Two-point score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>24.0 ± 2.9</td>
<td>23.5 ± 2.9</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>3 months</td>
<td>7.0 ± 2.4</td>
<td>13.3 ± 2.4</td>
<td>P &lt; 0.0001</td>
</tr>
<tr>
<td>6 months</td>
<td>−0.9 ± 1.8</td>
<td>6.8 ± 1.8</td>
<td>P = 0.02</td>
</tr>
</tbody>
</table>

*Data are presented as estimated mean ± standard error.

Figure 4 Digital images of the hairs on the “V” point at (a–c) 1-fold magnification and (d–f) 40-fold magnification. Female pattern hair loss in a patient (4) (a, d) before, (b, e) 3 months after and (c, f) 6 months after interfollicular injection of autologous CD34+ cell-containing platelet-rich plasma preparation.
Platelet-rich plasma

We suggested that a sufficient number of platelets could be obtained in all patients by using an automated PRP preparation system. Giusti et al. demonstrated that the optimal platelet concentration for the induction of angiogenesis in human endothelial cells was 1 500 000 platelets/L, whereas excessively high concentrations of platelets were suggested to decrease the angiogenic potential. In this study, a mean 1 484 555.6 platelets/μL in the PRP preparation could effectively stimulate follicular and perifollicular angiogenesis, which is suggested to be one of the major factors in active hair growth.7,10

The therapeutic use of autologous CD34+ haematopoietic stem cells has been proved to safely promote angiogenesis and vasculogenesis in ischemic conditions. Autologous bone marrow-derived CD34+ cell infusion to the infarct-related artery in patients with myocardial infarction showed significant therapeutic efficacies with ≥10 million CD34+ cells in a dose-dependent manner. Recently, Zhong et al. presented that bone marrow aspirate concentrate had CD34+ cells of 7.2 ± 6.9%, PRP preparation of 2.1 ± 2.2%, and peripheral blood of 0.48 ± 0.6% by FACS analyses. Both human bone marrow aspirate concentrates and

Figure 5  Digital images of the hairs on the ‘V’ point at (a–c) 1-fold magnification and (d–f) 40-fold magnification. Male pattern hair loss in a patient (7) (a, d) before, (b, e) 3 months after and (c, f) 6 months after interfollicular injection of autologous CD34+ cell-containing platelet-rich plasma preparation.

Figure 6  Digital images of the hairs on the ‘V’ point at (a–c) 1-fold magnification and (d–f) 40-fold magnification. Male pattern hair loss in a patient (8) (a, d) before, (b, e) 3 months after and (c, f) 6 months after interfollicular injection of autologous CD34+ cell-containing platelet-rich plasma preparation.
CD34+ cell-containing PRP preparations provided therapeutic benefits in bone regeneration without significant differences between groups.31 In this study, CD34+ cell counts in PRP preparations varied from 13.9 cells/µL to 31.1 cells/µL, 2.1- and 4.7-fold more concentrated CD34+ cells compared to peripheral blood mononuclear cells respectively. We suggest that the interfollicular injection of concentrated mobilized CD34+ cells in PRP preparations could have synergistic effects on the PRP-induced angiogenesis in patients with male and female pattern hair loss.

Our data suggest that the interfollicular injection of autologous CD34+ cell-containing PRP preparations has a positive therapeutic effect on male and female pattern hair loss without remarkable side-effects. However, the precise mechanisms of action of concentrated peripheral CD34+ cells in the hair growth cycling remain to be determined. Furthermore, optimized, prospective studies with a controlled/split scalp design should be conducted to confirm the clinical efficacies of CD34+ cells in patients with pattern hair loss.

Acknowledgement
We thank Hye Sun Lee, PhD (Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea) for her help with the statistical analyses and Dong-Su Jang (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Korea) for his help with the Figures.

References